Home › Companies › NBP

NovaBridge Biosciences

NBP Lead: Phase 2 2 Biotech Distilled articles ↓

Oncology Ophthalmology Protein

Most recent annual filing: 2026-04-07

Pipeline (6 active programs)

givastomig

Protein Target: CLDN18.2, 4-1BB

Gastric Cancer Phase 1 intravenous
Biliary Tract Cancer Phase 1 intravenous
Pancreatic Cancer Phase 1 intravenous

VIS-101

Protein Target: VEGF-A, ANG2

Wet Age-Related Macular Degeneration Phase 2 intravitreal

ragistomig

Protein Target: PD-L1, 4-1BB

Solid Tumors Phase 1 intravenous

uliledlimab

Protein Target: CD73

Non-Small Cell Lung Cancer Phase 2 intravenous

Biotech Distilled coverage (2)

Articles open on Substack. Some deep dives are subscriber-only.